Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Incidental thyroid uptake is found in approximately 2.5% of patients who undergo FDG PET for nonthyroid malignancy; approximately a third of the FDG PET thyroid incidentalomas are malignant, including primary thyroid malignancies and metastasis. 31135518 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma. 30809525 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE The present study aimed to evaluate the reliability of <sup>18</sup> F-FDG PET/CT in stratifying the risk of malignancy in these lesions. 30740757 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE PET/CT and PET/MRI images were evaluated by two readers independently for areas of FDG uptake compatible with malignancy, and then categorized into 5 groups (1: PET/MRI and PET/CT positive; 2: PET/MRI positive, PET/CT positive in retrospect; 3: PET/CT positive, PET/MRI positive in retrospect; 4: PET/MRI positive, PET/CT negative; 5: PET/MRI negative, PET/CT positive) by consensus. 28103230 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Multicenter external validation of two malignancy risk prediction models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation. 27631108 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Lymph node tuberculosis mimicking malignancy on <sup>18</sup>F-FDG PET/CT in two patients: A case report. 28587415 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE The case suggests that HLRCC should be considered in any young patient with bulky uterine leiomyomas and renal cell cancer, and F-FDG PET/CT can help detect unexpected additional primary malignancy in a patient with known cancer. 28737576 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE However, the increase in risk among heterozygotes in the two SNPs in SMUG1, which is thought to be the most active glycosylase in vivo, raises the possibility that subtle 'heterosis' effects on cancer risk might be produced by these SNPs. 21427733 2011
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE F-FDG PET-CT images before treatment, and data including response to treatment, local recurrence, death due to the cancer, disease-free survival (DFS) and primary relapse-free survival (PRFS), were collected for analysis.The Wilcoxon rank test showed that all values determined by the different delineation techniques were significantly different from the GTVp (P < .05). 28658110 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE In this patient, a series of imaging modalities including MRI, bone scan, and F-FDG PET/CT revealed only 1 solitary osseous lytic lesion with abnormal uptake in the third thoracic vertebra, suggesting a primary skeletal malignancy. 30222679 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Independent predictors for malignancy in IPMN were as follows: 18-FDG PET accumulation, CEA >1.0 ng/ml, and NLR >2.63. 31092444 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE <sup>18</sup>FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. 29743108 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Can <sup>18</sup>F-FDG PET predict the grade of malignancy in thymic epithelial tumors? An evaluation of only resected tumors. 29263700 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE A 67-year-old woman with prolonged fever, thrombocytopenia, and renal dysfunction underwent FDG PET/CT to evaluate underlying causes, including malignancy. 30222681 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE 2-FDG LC variations have been especially significant in tumors, particularly at different stages of cancer development, affecting the accuracy of quantitative glucose measures and potentially limiting the prognostic value of 2-FDG, as well as its accuracy in monitoring treatments. 31676728 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE The 122 recipients underwent a total of 133 FDG PET/CT scans performed for a suspected malignancy (66 %) or an infection (34 %). 27838763 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 GeneticVariation group BEFREE Sixty-eight patients with sinonasal cancer who underwent both pretreatment <sup>18</sup> F-FDG PET/CT scan and head-neck MRI from January 2009 through August 2017 were retrospectively reviewed. 31041831 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE A 74-year-old man with multiple soft tissue lesions in the lung, which were suspected to be metastatic neoplasms, underwent F-FDG PET/CT scan to detect primary malignancy. 30004935 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE To assess the performance of 18F-FDG PET/CT in the malignancy diagnosis of adrenal masses in noncancer patients. 28431167 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE FDG PET/CT was performed to exclude underlying malignancy. 28481801 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE Metabolic information obtained through <sup>18</sup>F-flurodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC). 31502013 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE The significance of <sup>18</sup>F-FDG PET/CT in the detection of malignancy, observation of activity of myopathy, and determination of interstitial lung disease in IIM patients was explored based on the final clinical diagnosis. 28831580 2017
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE FDG accumulation in the gallbladder has been reported as an indication of either malignancy or inflammation. 29485432 2018
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE The mechanism of <sup>18</sup>F-FDG uptake within cancer cells involves the glucose transporter 1 (GLUT1) and hypoxia-inducible factor-1 α (HIF-1α). 31319979 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE <sup>18</sup>F-FDG avidity in the index malignancy, an advanced stage for that malignancy, and a clinician decision not to investigate <sup>18</sup>F-FDG-avid TI were all predictors of mortality, with hazard ratios of 8.5, 3.0, and 3.3, respectively, and 95% confidence intervals of 4.6-15.8, 2.3-3.9, and 2.0-5.0, respectively (<i>P</i> < 0.001). 29025986 2018